Eden Empire Inc.

OTC: EDNEF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#1001 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 18

v0.1 · 5/100 weight · pillars only

↑ return on assets, balance-sheet leverage · ↓ return on equity, disclosure history

Methodology →

Revenue TTM

$171.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.1M

Employees

—

Market cap

$68.6k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$171.0k217.9k CAD2021

Net income-$3.1M-4.0M CAD2021

Operating income-$2.3M-2.9M CAD2021

Total assets$3.5M4.4M CAD2021

Liabilities$3.3M4.1M CAD2021

Equity$107.3k133.7k CAD2021

Revenue trend

FY2019 – FY2021 · USD

FY19

FY20

$171.0k

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Eden Empire Inc. booked $171.0k in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -1818.9% net margin.

Peers · Healthcare

Novo Integrated Sciences, Inc.——South American Gold Corp.——Item 9 Labs Corp.——Pathfinder Cell Therapy, Inc.——

Key facts

CEODavid Gdanski

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: EDNEF

Employees—

IPO date2021-08-19

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.